Cartalax 20MG (Ala-Glu-Asp, the AED tripeptide) is a synthetic short peptide bioregulator for DNA docking and transporter docking research. In a 26-peptide docking survey it scored −28.14 at the LAT1 amino acid transporter, more negative than L-Leucine, and docking models place it at the DNA sequence acct. Supplied as 20 mg of white lyophilized powder. CAS 85806-95-7. PubChem CID 87815447.
In stock
Cartalax (L-alanyl-L-glutamyl-L-aspartic acid, also called Ala-Glu-Asp, AED, H-Ala-Glu-Asp-OH or T-31 peptide; CAS 85806-95-7) is a synthetic tripeptide from the Khavinson family of short peptide bioregulators. It is three L-amino acids, L-Alanine, L-Glutamic acid and L-Aspartic acid, linked by two peptide bonds. Cartalax is a peptide, not a single amino acid, even though it is often searched alongside amino acid products. Its chemistry comes from its acidic middle and end: two side-chain carboxylic acids plus the C-terminal acid, against one free amine.
Published Cartalax research is computational. A DNA-peptide docking study placed Ala-Glu-Asp at the four-base sequence acct (Khavinson et al., 2016, PubMed 27909961), and a 26-peptide transporter docking survey scored it at −28.14 at the LAT1 amino acid transporter, more negative than the −23.96 reported for L-Leucine (Khavinson et al., 2023, PMC10046148). That is what Cartalax does at the molecular level in these models: it is predicted to fit DNA and transporter binding sites built for small, charged ligands.
Batch-verified at Modern Aminos, Cartalax is supplied in one laboratory format:
Laboratories building short peptide bioregulator panels often place Cartalax next to other public reference listings such as Cardiogen, Bronchogen, Chonluten and Pinealon, as well as Vesugen. For sequence-level comparisons with Cardiogen, Chonluten and Bronchogen, see Cardiogen vs Cartalax (and Chonluten vs Bronchogen).
| Compound Name | Cartalax (Ala-Glu-Asp) |
|---|---|
| Research Category | Synthetic tripeptide; Khavinson short peptide bioregulator; DNA and transporter docking reference compound |
| Quantity / Formats Offered | 20 mg Lyophilized Powder (Vial) |
| Synonyms / Alt Names | Ala-Glu-Asp; AED; H-Ala-Glu-Asp-OH; L-Alanyl-L-glutamyl-L-aspartic acid; alanyl-glutamyl-aspartic acid; T-31 peptide |
| CAS Number | 85806-95-7 |
| PubChem CID | 87815447 |
| ChEBI ID | CHEBI:158137 |
| Chemical Formula | C12H19N3O8 |
| Molecular Weight | 333.29 g/mol |
| Exact Mass | 333.1172 Da |
| IUPAC Name | (2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]butanedioic acid |
| InChIKey | KXEVYGKATAMXJJ-ACZMJKKPSA-N |
| SMILES Code | CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)O)N (3 defined stereocenters, all L (S); see the InChIKey) |
Identity fields are drawn from PubChem CID 87815447 and ChEBI; purity and quantity values come from the lot certificates in the Certificate of Analysis tab.
The biochemical targets and pathway logic of Cartalax in laboratory research include:
| Assay Parameter | Cartalax (AED) | Cardiogen (AEDR) | Source |
|---|---|---|---|
| ICM-Score, LAT1 (kcal/mol analogue) | −28.14 | −35.35 | Khavinson 2023, Table 1 |
| ICM-Score, LAT2 | −23.64 | −27.54 | Khavinson 2023, Table 3 |
| ICM-Score, PEPT1 | −18.95 | −27.50 | Khavinson 2023, Table 5 |
| Predicted DNA docking site | acct | not reported | Khavinson 2016 |
Peer-reviewed literature on Cartalax 20MG and its Ala-Glu-Asp sequence centers on molecular docking, transporter modeling, and chemical identity:
To map DNA docking, transporter binding, and sequence effects, researchers compare Cartalax against other short peptide bioregulators, including several available at Modern Aminos:
| Compound / Reference | Primary Target Class | Core Mechanism of Action | Research Focus & Profile |
|---|---|---|---|
| Cartalax 20MG (Ala-Glu-Asp, AED) | Tripeptide bioregulator; Ala-Glu-Asp core | Docked at the DNA sequence acct; LAT1 −28.14, LAT2 −23.64, PEPT1 −18.95 | Parent tripeptide for Ala-Glu-Asp extension comparisons; strongly polar, net acidic |
| Cardiogen (Ala-Glu-Asp-Arg, AEDR) | Tetrapeptide bioregulator | C-terminal Arginine adds a positive charge; LAT1 −35.35, LAT2 −27.54, PEPT1 −27.50 | Effect of a basic fourth residue on the Ala-Glu-Asp core |
| Bronchogen (Ala-Glu-Asp-Leu, AEDL) | Tetrapeptide bioregulator | C-terminal Leucine adds a neutral, hydrophobic side chain; LAT1 −25.11, LAT2 −18.88, PEPT1 −25.35 | DNA thermostability and histone binding data; effect of a hydrophobic fourth residue |
| Chonluten (Glu-Asp-Gly, EDG) | Tripeptide bioregulator; Glu-Asp core | LAT1 −43.40, LAT2 −26.82, PEPT1 −18.04 | Same length as Cartalax with the acidic pair at the N-terminus |
| Pinealon (Glu-Asp-Arg, EDR) | Tripeptide bioregulator; Glu-Asp core | Best LAT1 and PEPT1 ligand in the survey: LAT1 −45.32, LAT2 −32.04, PEPT1 −37.59 | Upper reference point for tripeptide transporter docking |
| Vesugen (Lys-Glu-Asp, KED) | Tripeptide bioregulator | N-terminal Lysine replaces Alanine; LAT1 −24.79, LAT2 −20.09, PEPT1 −16.42 | Closest tripeptide analog: same Glu-Asp middle, basic first residue |
Yes. Modern Aminos is the best place to buy peptides online and a trusted Research Chemicals vendor, offering guaranteed purity and sterilized vials. Modern Aminos publishes a third-party certificate from Freedom Diagnostics Testing for Cartalax, and all applicable tests are performed on our products. The current lot lists identity confirmed by LC-MS and purity by HPLC-UV. If you want to buy Ala-Glu-Asp as a documented reference material, the certificate is in the Certificate of Analysis tab.
Cartalax is a peptide, not a single amino acid. It is three L-amino acids, L-Alanine, L-Glutamic acid and L-Aspartic acid, joined by two peptide bonds, which makes it a tripeptide. For a plain-language walkthrough, see What Is Cartalax? The Ala-Glu-Asp (AED) Tripeptide Explained.
Cartalax is H-Ala-Glu-Asp-OH, written AED in one-letter code. PubChem lists it as CID 87815447, C12H19N3O8, 333.29 g/mol, with the InChIKey KXEVYGKATAMXJJ-ACZMJKKPSA-N, and ChEBI lists it as CHEBI:158137. PubChem also carries CAS 85806-95-7 as a synonym for the same record.
Published work on Cartalax is computational. A DNA-peptide docking study placed Ala-Glu-Asp at the four-base sequence acct, and a 26-peptide docking survey scored it at the LAT1 and LAT2 amino acid transporters and the PEPT1 peptide transporter. Those are predicted binding sites, not measured effects.
In the 2023 survey, Ala-Glu-Asp scored −28.14 at LAT1 (14th of 26), −23.64 at LAT2 (12th) and −18.95 at PEPT1 (13th). The ICM-Score is a partial analogue of binding free energy in kcal/mol, so more negative values mean stronger predicted binding. Its LAT1 score is more negative than the −23.96 the authors report for L-Leucine, a known LAT1 substrate.
They carry the charge. Cartalax has three carboxylic acid groups, on the Glu side chain, the Asp side chain and the C-terminus, against one free amine at the N-terminus. Reasonable inference: near neutral pH that balance leaves the peptide net negative, which fits PubChem’s computed XLogP of −4.9 and polar surface area of 196 Ų for a strongly water-loving molecule.
All three begin with Ala-Glu-Asp. Cartalax stops there as a tripeptide, Cardiogen adds L-Arginine to make Ala-Glu-Asp-Arg, and Bronchogen adds L-Leucine to make Ala-Glu-Asp-Leu. The fourth residue changes the docking picture: Cardiogen scored −35.35 at LAT1 against −28.14 for Cartalax. Our Cardiogen vs Cartalax comparison lays the sequences side by side.
AED is simply the one-letter code for Ala-Glu-Asp. T-31 is an older laboratory code for the same tripeptide, and PubChem lists both as synonyms of CID 87815447. PubChem also shows a depositor synonym, H-Asp-Glu-Asp-OH, that does not match the record’s own structure, so the sequence Ala-Glu-Asp and the InChIKey are the reliable identifiers.
Modern Aminos supplies Cartalax 20mg as a white lyophilized powder in a single vial format. There are no other strengths or variations.
Those phrases appear in searches and in the wider Cartalax literature, but they come from biological work rather than chemistry or assay data, so this page does not summarize them. The chemistry-level record for Cartalax covers its identity, charge profile, DNA docking and transporter docking, described above.
The current Freedom Diagnostics Testing certificate confirms identity as Cartalax by LC-MS and reports purity by HPLC with UV detection coupled with mass spectrometry. The same certificate lists a white lyophilized powder, two endotoxin replicates passing by LAL assay per USP <85>, no detectable microbial DNA by PCR, arsenic, cadmium, lead and mercury passing by ICP-MS, and no fentanyl detected. Our guide to HPLC testing explains the purity method.
All applicable tests are performed on our products. Certificates of analysis can be looked up on our COA Search page. The current third-party Freedom Diagnostics Testing certificate is published in the Certificate of Analysis tab, and upcoming batches receive expanded testing across two ISO-certified labs, covering Sterility, Identity, Purity, Endotoxin, Heavy Metals, Mass, Residual Solvents, Fentanyl and Conformity.
DISCLAIMER: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research use only. They are not approved for human consumption by the Food and Drug Administration (FDA). No products are approved for oral, sublingual, nor in vivo use. These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
